You are here

CAR-T

Better than CAR-T? Already prepping for a US launch, MorphoSys posts stellar DLBCL data to field against Novartis, Gilead

Better than CAR-T? Already prepping for a US launch, MorphoSys posts stellar DLBCL data to field against Novartis, Gilead

Endpoints

Gilead Sciences

Flag link:

Novartis takes another step forward in global Kymriah rollout as Japan OKs the drug at $305K

Novartis takes another step forward in global Kymriah rollout as Japan OKs the drug at $305K

Endpoints

Flag link:

Gilead's first move under new chief is to untether Kite

Gilead's first move under new chief is to untether Kite

Biopharma Dive

Gilead Sciences

Flag link:

Celgene reports 'durable' responses to multiple myeloma CAR-T in early trial despite relapses

Celgene reports 'durable' responses to multiple myeloma CAR-T in early trial despite relapses

Fierce Biotech

Multiple Myeloma

Flag link:

Tessa showcases preclinical promise of 'all-in-one' add-on to its cancer cell therapy, in march to the clinic

Tessa showcases preclinical promise of 'all-in-one' add-on to its cancer cell therapy, in march to the clinic

Endpoints

Tessa Therapeutics

virally-associated tumors

Flag link:

How a Medicare Rule Change Could Bring CAR-T Stocks Back to Life

How a Medicare Rule Change Could Bring CAR-T Stocks Back to Life

Motley Fool

Gilead Sciences

Flag link:

Kite's CAR-T manufacturing gets another boost with new Maryland facility

Kite's CAR-T manufacturing gets another boost with new Maryland facility

Fierce Pharma

Gilead Sciences

drug manufacturing

Flag link:

Medicare proposes raising CAR-T pay, but reimbursement solution years away

Medicare proposes raising CAR-T pay, but reimbursement solution years away

Biopharma Dive

Flag link:

With some tweaks, CAR-T cancer therapy could be made safer — and more widely available — study suggests

With some tweaks, CAR-T cancer therapy could be made safer — and more widely available — study suggests

Stat

Flag link:

Redesigned CAR-T eliminates dangerous cytokine release syndrome in lymphoma trial

Redesigned CAR-T eliminates dangerous cytokine release syndrome in lymphoma trial

Fierce Biotech

cytokine release syndrome

Flag link:

CAR-T Drugmaker Poseida Snags $142 Million in Financing Led by Novartis

CAR-T Drugmaker Poseida Snags $142 Million in Financing Led by Novartis

BioSpace

Poseida Therapeutics

Flag link:

4 Medtech Innovations That Are Tearing up the Script

4 Medtech Innovations That Are Tearing up the Script

Medical Devices and Diagnostics Industry

neurostimulation

machine learning

artificial intelligence

Flag link:

Autolus follows up CAR T data with $101M raise

Autolus follows up CAR T data with $101M raise

BioCentury

Flag link:

Eyeing a fast pitch for quick OK in race with bluebird, J&J/Legend team enjoys a regulatory embrace for their rival BCMA CAR-T

Eyeing a fast pitch for quick OK in race with bluebird, J&J/Legend team enjoys a regulatory embrace for their rival BCMA CAR-T

Endpoints

Flag link:

AACR: After blood cancer successes, CAR-T treatments see inroads for solid cancers

AACR: After blood cancer successes, CAR-T treatments see inroads for solid cancers

Fierce Biotech

Flag link:

Biotech’s newborn unicorn Sana grabs Harvard tech aimed at slipping engineered stem cells past the immune system

Biotech’s newborn unicorn Sana grabs Harvard tech aimed at slipping engineered stem cells past the immune system

Endpoints

Sana Biotechnology

Flag link:

Hospitals are saving lives with CAR-T. Getting paid is another story

Hospitals are saving lives with CAR-T. Getting paid is another story

Stat

Flag link:

Beyond cancer: CAR T cells treat lupus in mice

Beyond cancer: CAR T cells treat lupus in mice

BioCentury

Flag link:

Xenetic Biosciences to Acquire Personalized CAR T Platform

Xenetic Biosciences to Acquire Personalized CAR T Platform

CP Wire

Xenetic Biosciences

Flag link:

Xenetic Biosciences to Acquire Personalized CAR T Platform

Xenetic Biosciences

Flag link:

Pages